The Gout Stop Programme was developed for primary care in Northland, New Zealand, to address inequitable health outcomes for Māori and Pacifi c people with gout.
Introduction
Gout, a common type of infl ammatory arthritis, is a chronic disease that occurs with elevation of serum urate, causing the formation and deposition of monosodium urate crystals within joints. 1 Although a chronic condition, patients oft en present with recurrent fl ares, which are acute and extremely painful events. Metabolic syndrome, renal impairment, hereditary factors and diuretics are key risk factors for gout. 2 In 2016, it was estimated that gout aff ected ~5.2% of New Zealanders. 3 In Northland, gout prevalence was 7.7%. 3 In Māori and Pacifi c peoples, the prevalence of gout is higher than for non-Māori/non-Pacifi c people. Sixty percent of the variation in urate levels between individuals can be attributed to inherited genetic variants. 4 Māori and Pacifi c peoples increased prevalence of gout can be partly explained by reduced renal excretion of uric acid. Key proteins for the renal excretion of uric acid are aff ected by the genes SLC2A9 and ABCG2, with the SLC2A9 genetic variant more prevalent in Māori and Pacifi c people. 5 Oral urate-lowering therapy is eff ective in reducing serum urate levels to below the saturation point for monosodium urate crystals, inhibiting formation and inducing dissolution of these crystals. Th is eff ectively counteracts the cause of the acute pain symptoms of gout and reduces future joint deformities. Gout can be eff ectively managed with allopurinol, provided it is started at a low dose and titrated upwards monthly until the target urate level of <0.36 mmol L -1 is achieved. Th is treatment has been available for years, yet most people do not receive eff ective treatment and suff er from the painful symptoms of gout. 1 Inadequate treatment may be due to beliefs and stigma surrounding gout, to prescriber knowledge, variable approaches to treatment or the target urate level not being achieved or maintained. A short course of prednisone and colchicine can be used to control symptoms of acute gout and fl are ups during initiation of urate-lowering therapy.
Th e Gout Stop programme is based on the publication entitled ' Treating acute gout and starting prevention in 7 minutes '. 6 Goldfi en et al . 7 in the US and Phone 8 in New Zealand have published other pharmacist-led collaborative programmes, but neither included a community support worker role. Northland's high Māori and Pacifi c populations, 9 the inequity of gout-related health outcomes in Māori and Pacifi c people 3 and the need to individualise treatment to achieve successful gout prevention and management are further driving factors promoting the development of the Gout Stop Programme. Th e programme aims to discover and reduce barriers to accessible gout treatment, specifi cally for Māori and Pacifi c people, and thereby achieve equity of health outcomes.
A common barrier to managing gout eff ectively is that patients may have a limited understanding of the condition and its treatment. 10 , 11 Building on patient knowledge and providing information for people at risk of, or with, gout is needed to improve health outcomes. 10 In addition, raising awareness and understanding of gout in the community is important.
Based on the positive outcomes and lessons from a pilot project involving 20 patients in 2014, the programme was modifi ed to include an option for diabetic patients and inclusion of community support workers, and was rolled out progressively to clinicians across Northland. Th e treatment protocol was endorsed by rheumatologists and the renal team at Whangarei Hospital. A target of >70% Māori and Pacifi c patient participation
WHAT GAP THIS FILLS
What is already known : Gout prevalence is disproportionally high in Māori and Pacifi c people and is often undertreated in this group of people compared to non-Māori and non-Pacifi c people. Uratelowering treatment is effective, yet patients with gout are often poorly managed with sub-optimal treatment.
What this study adds : The Gout Stop Programme highlights the importance of empowering patients to understand the management and prevention of gout, particularly among Māori and Pacifi c populations. Collaboration between general practitioners, community pharmacists, community support workers and health organisations is important in initiating prevention in high-needs populations who have the greatest gout prevalence, and in establishing patients on long-term allopurinol treatment. ) and presence of diabetes as a comorbidity. In the diabetes option, naproxen was selected instead of prednisone. Th e prescription option, known as the ' Gout Stop Pack ' and specifi c programme laboratory form were built into Practice Management System (Medtech 32, Medtech Global Limited, Auckland, New Zealand), allowing easy selection by clinicians ( Box 2 ). A ' GP
Box 1. Inclusion and exclusion criteria
Inclusion criteria:
• Clinical diagnosis of acute gout attack.
• Vital signs within range (temperature <37C, BP systolic >100 mm Hg, HR <100 bpm).
• Patient can move joint despite pain.
• Attacks ≥2 per annum. Exclusion criteria: (Refer to a rheumatologist)
• Doubt about diagnosis.
• Septic arthritis.
• Avoid treatment with colchicine if eGFR (estimated glomerular fi ltration rate) <10. The option for diabetic patients with an eGFR <60 is to consider the Gout Stop Pack -Option 2 or 3 with reduced prednisone dose (consider halving the dose) or consult a renal physician.
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Flow Chart ' described the process followed during the programme ( Box 3 ).
Medication was dispensed by a community pharmacist according to the prescription for the ' Gout Stop Pack '. Th e medication was provided in free-of-charge blister packaging on four occasions and regular contact was maintained to guide patients through the process. Patients were advised when to have laboratory tests, the serum urate result was checked in the clinical information sharing service, TestSafe, and the level and patient outcome was communicated to the prescriber.
Patients who completed the programme were categorised based on their serum urate levels as follows: No level : patient completed the programme but no serum urate level was available.
Patients who did not complete the programme were categorised based on the reason for noncompletion as follows:
Disengaged : patient disengaged due to personal or social factors.
Withdrawn : patient was removed by the prescriber or specialist due to comorbidities or side-eff ects.
Lost to follow up : patient was uncontactable or had moved away.
Community pharmacists were contacted either by telephone or email between April and December 2017 to determine whether two cohorts of patients had allopurinol prescribed following completion of the programme. Pharmacists used the booklet ' To Stop Gout ' 12 as an education tool to give to patients. An informative video about the programme and its benefi ts was created; this includes narratives from both the health-care team and patients who participated in the programme. 13 In consultation with Emergency Department clinicians, patients presenting to Emergency Department with acute gout were prescribed 2 weeks of prednisone and given a voucher for a free-of-charge GP visit in order to be enrolled in the programme. Patients were followed up and outcomes recorded.
Arthritis New Zealand Gout Educators provided support to patients who consented until September 2017. A Gout Kaiāwhina role was then created to support patients in the programme, link patients with clinicians and community pharmacists, and reach patients in occupations with a high percentage of Māori males in the workforce.
Patient outcome questionnaire
A cohort of 24 patients, 12 in each of the Māori and Pacifi c and non-Māori/non-Pacifi c groups and three in each outcome group (Success, Titration, No Level) were randomly selected (using www.random.org ). A questionnaire based on open-ended questions, as listed in Table 1 , was used to collect qualitative information from these 24 randomly selected patients. Th e overall rating of the programme used a scale of 0-4, where 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent. Telephone interviews with patients enrolled in the programme in the previous 16 months were conducted by a medical student working on a summer internship, and responses were documented.
Results

Demographics
A total of 887 patients were enrolled in the programme. Demographic data are presented in Table 2 . Th e mean age of Māori and Pacifi c males was 9 years younger than Māori and Pacifi c females. Māori and Pacifi c males and females presented with gout younger than other ethnicities ( Figure 1 ) . Th e percentage of Māori and Pacifi c patients was higher than the percentage population for Northland according to census data. 9 
Treatment outcomes
Th e programme was adopted by 36 general practices across Northland. A total of 160 clinicians, including GPs, specialist physician, nurse practitioners and clinicians from Māori health providers, prescribed the programme. Data for 708 patients were analysed, representing 80% of enrolled patients. Th e remaining 20% of patients are still in the programme or the data had not yet been obtained. Of the three treatment options shown in Box 2 , 74% of patients were allocated to option 1, 18% to option 2, 1% to option 3, 3% to the diabetes alternative option and the remaining 4% had no option recorded. Of the total number of patients who completed the programme, 66% (299/450) continued to take allopurinol following completion; 68% (189/280) of Māori and Pacifi c patients and 65% (110/170) of the non-Māori/non-Pacifi c group. Eighty-eight patients were enrolled in the programme on more than one occasion; 68 were enrolled on two occasions, 18 on three occasions and two on four occasions. Of these patients, 89% were Māori and 42% have since completed the programme.
Patients who presented in the Emergency Department (ED) with gout and were referred to the programme were followed up by telephone. Seven patients, with 14 presentations to the ED as a result of two patients presenting multiple times, were contacted. On seven occasions, patients were provided a GP voucher and three patients visited a GP and were enrolled in the programme. 
Patient outcome questionnaire
Of the 24 patients identifi ed for interview, 21 were contactable and were interviewed (11 Māori and 10 non-Māori patients). Of these, 16 patients had completed the programme, 13 confi rmed that they were still taking the allopurinol and eight recalled having been informed that the medication was required to be taken long term. Most patients (62.5%) had a serum urate test on completion of the programme. Th e overall rating of the programme was recorded as excellent by 62% of patients and very good by 38%. Th e questions asked and patient responses are summarised in Table 1 .
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Discussion
New Zealand research has shown that gout is undertreated and that approximately twothirds of patients with gout dispensed uratelowering therapy have not had serum urate levels measured in the following 6 months. 3 Consistent with other reports of gout disproportionally aff ecting people of Māori or Pacifi c decent, 14 the demographic analysis in this research demonstrated a high number of Māori and Pacifi c people. While the initial goal of enrolling patients in the programme being >70% Māori and Pacifi c people was achieved, the rate of programme completion was lower in the Māori and Pacifi c group (55%) compared to the nonMāori/non-Pacifi c group (84%). Successful completion of the programme was also lower in Māori and Pacifi c patients at 40% versus 51% in non-Māori/non-Pacifi c patients.
Factors related to the perception of gout, insuffi cient understanding of treatment and adherence to long-term treatment, appear to contribute to this disparity. 15 Th is emphasises the need for a fl exible programme and the informative role of the Gout Kaiāwhina. Of the patients enrolled more than once, 42% of patients, of whom 89% are Māori, have since completed the programme, suggesting that the re-enrolment of patients is important when addressing health outcome inequities.
Th ere appears to be a need to raise the profi le of gout, emphasise the appropriate use of uratelowering therapy, as well as the importance of a multiple therapy approach to treating acute gout attacks. Urate levels require monitoring on a regular basis, the dose of urate-lowering therapy needs to be adjusted accordingly and prescribed on a long-term basis. Th e Gout Stop Programme addresses these issues directly by aiding interprovider collaboration, increasing support for health literacy and ease of prescribing.
In 2016, the Atlas of Health Care variation data for gout in Northland showed a rate of allopurinol use of 43.2% compared to the national rate of 41.6%. In Māori males, the rates were 41.5% in Northland and 39.5% nationally. Th e rate of non-steroidal anti-infl ammatory drug (NSAID) use in patients with gout was lower in Northland at 34.6% compared to the national rate of 37.1%. Among Māori males, the rates were 40.2% and 43.6% respectively (A. Wevers, pers. comm., HQSC, February 2018). It thus appears A US study 7 assessed the eff ect of a pharmaciststaff ed gout management clinic and found this more eff ective than usual care under a primary care physician or rheumatologist in achieving target serum urate levels in gout patients. In NZ, Owning My Gout is a pharmacist-led collaborative gout management project involving community pharmacists and practice nurses where an electronic shared care plan is initiated and community pharmacists titrate allopurinol doses in collaboration with the general practice team. Th is project demonstrated that community pharmacists can have a role in the titration of allopurinol dosing using standing orders provided by GPs. 8 Th e ultimate success for patients is reaching the serum urate target of ≤0.36 mmol L -1 and continuing to take allopurinol as a long-term medication, to avoid acute gout fl ares and joint deformities. We found that 68% of Māori and Pacifi c patients continued taking allopurinol aft er completion of the programme. Patients require a comprehensive understanding of the treatment and the need for adherence. Longitudinal monitoring of the project will track the programme's eff ect on patient outcomes and allow for modifi cations to the programme in order to achieve higher rates of long-term allopurinol use.
Th e patient outcome questionnaire showed a disparity between the number of patients confi rming they were still taking allopurinol and the number with a good understanding of the need for long-term treatment. Th is highlights the need for reinforcing patient education and ensuring patient understanding. Reasons for patients not accessing serum urate blood tests were captured as this is an issue documented in previous studies. 16 Th is, along with the fact that 32% of patients who completed the programme had no serum urate measured, supports the recent modifi cation of the programme to include Point-of-Care testing in community pharmacies using BeneCheck meters and urate test strips as an on-site alternative to laboratory tests, and to facilitate appropriate dosing of allopurinol for individual patients at the time of medication dispensing. Th is approach demonstrates a collaborative and fl exible programme that is geared towards meeting the goals and needs of patients and providers.
In 2017, 182 patients presented to the ED at Whangarei Hospital with the primary diagnosis of gout; 69% were Māori, of whom 79% were males (B. Johnson, pers. comm., NDHB, March 2018). A small number of patients were referred to the programme from the ED, suggesting that the process did not meet the needs of all patients or that clinicians were not aware of the programme. Referral of patients between secondary and primary care is important when initiating prevention and treatment of gout in high-needs populations. It is therefore important to understand why people access the ED for non-emergency conditions and to continuously review processes to simplify the path of accessing treatment. Similar to suggestions from other studies, 10 there should be a shift in the management of gout from a recurrent acute condition to management as a chronic disease for which there are successful long-term multidisciplinary treatment options. Primary care has a key role in coordinating the prevention and management of such conditions. Th e programme was prescription driven and relied on patients being seen by clinicians who had access to the treatment protocol, the presentation and dispensing of prescriptions at community pharmacies, and referral to the Gout Kaiāwhina for support. Th e data collected were derived from completed patient record forms returned from community pharmacy and participation was open and uncontrolled. Th e number of patients interviewed was small and only 21 of 24 were contactable, but responses provided lessons for the programme.
Th e Gout Stop Programme is being expanded to include more structured and culturally appropriate gout education in community pharmacies, enhanced identifi cation of potential gout patients who would benefi t from the programme, as well as the identifi cation of patients with gout who present in community
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J OURNAL OF PRIMARY HEALTH CARE pharmacies for over-the-counter NSAIDs with the aim of referring them to a GP.
Conclusion
Th e Gout Stop Programme highlights the importance of empowering patients to understand the management and prevention of gout, particularly among Māori and Pacifi c populations. Māori and Pacifi c males present younger, yet have lower levels of programme completion. To achieve improved medication adherence and gout-related health outcomes, culturally appropriate education and support for patients and whānau are required.
Collaboration between GPs, community pharmacists, community support workers and health organisations is important in initiating prevention in high-needs socioeconomic populations, who have the greatest gout prevalence, and in establishing patients on long-term allopurinol treatment. Each group of health-care professionals has a key role to play in the identifi cation of patients with gout, in successful acute and long-term treatment of gout, and in improvement of equity in health outcomes.
Removing barriers to access of appropriate treatment and serum urate testing is crucial to successful long-term gout management. Th e importance of treatment adherence and serum urate testing needs to be explained to patients in a comprehensible manner. Clear communication pathways between patients and members of the health-care team is essential in ensuring that all have the information needed to initiate treatment, titrate allopurinol doses and achieve successful long-term outcomes. Th e Northland Gout Stop programme is evidence based, fl exible in approach and makes use of patient outcomes and feedback to inform on-going primary care service delivery, with encouraging results to date.
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